Heron Therapeutics (HRTX) Equity Average (2011 - 2026)

Heron Therapeutics has reported Equity Average for 16 years, with the latest figure at $11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 137.79% year-over-year to $11.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 137.79% YoY), and the FY2025 full-year result was -$9.7 million, up 71.43% from the prior year.
• Equity Average for Q1 2026 stood at $11.7 million, down from $14.6 million in the prior quarter.
• The five-year high for Equity Average was $50.8 million in Q1 2022, with the low at -$39.0 million in Q3 2024.
• Historically, Equity Average has averaged -$11.9 million across 5 years, with a median of -$25.4 million in 2023.
• Annual changes were most pronounced in 2023 — Equity Average sank 9493.56% — and 2025, when it jumped 139.67%.
• Heron Therapeutics' Equity Average stood at $18.0 million in 2022, then plunged by 271.45% to -$30.9 million in 2023, then declined by 19.26% to -$36.8 million in 2024, then jumped by 139.67% to $14.6 million in 2025, then declined by 19.67% to $11.7 million in 2026.
• The last three Equity Average figures came in at $11.7 million (Q1 2026), $14.6 million (Q4 2025), and -$6.2 million (Q3 2025), per Business Quant data.